195 related articles for article (PubMed ID: 36899869)
1. Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction.
Jehl A; Conrad O; Burgy M; Foppolo S; Vauchelles R; Ronzani C; Etienne-Selloum N; Chenard MP; Danic A; Dourlhes T; Thibault C; Schultz P; Dontenwill M; Martin S
Cells; 2023 Feb; 12(5):. PubMed ID: 36899869
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
[TBL] [Abstract][Full Text] [Related]
3. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
4. Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab.
Liu S; Yan S; Zhu J; Lu R; Kang C; Tang K; Zeng J; Ding M; Guo Z; Lai X; Jiang Y; Wu S; Zhou L; Sun L; Zhou ZW
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012290
[TBL] [Abstract][Full Text] [Related]
5. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
[TBL] [Abstract][Full Text] [Related]
6. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
[TBL] [Abstract][Full Text] [Related]
7. Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on
Job S; Reyniès A; Heller B; Weiss A; Guérin E; Macabre C; Ledrappier S; Bour C; Wasylyk C; Etienne-Selloum N; Brino L; Gaiddon C; Wasylyk B; Jung AC
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181806
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
9. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
[TBL] [Abstract][Full Text] [Related]
10. Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.
Burgy M; Jehl A; Conrad O; Foppolo S; Bruban V; Etienne-Selloum N; Jung AC; Masson M; Macabre C; Ledrappier S; Burckel H; Mura C; Noël G; Borel C; Fasquelle F; Onea MA; Chenard MP; Thiéry A; Dontenwill M; Martin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207120
[TBL] [Abstract][Full Text] [Related]
11. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
[TBL] [Abstract][Full Text] [Related]
12. SENP1 inhibits ferroptosis and promotes head and neck squamous cell carcinoma by regulating ACSL4 protein stability via SUMO1.
Xu X; Mao Y; Feng Z; Dai F; Gu T; Zheng J
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186303
[TBL] [Abstract][Full Text] [Related]
13. Ferroptosis promotes anti-tumor immune response by inducing immunogenic exposure in HNSCC.
Zhao YY; Lian JX; Lan Z; Zou KL; Wang WM; Yu GT
Oral Dis; 2023 Apr; 29(3):933-941. PubMed ID: 34773344
[TBL] [Abstract][Full Text] [Related]
14. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
15. Epithelial Membrane Protein 1 Promotes Sensitivity to RSL3-Induced Ferroptosis and Intensifies Gefitinib Resistance in Head and Neck Cancer.
Wang Y; Zhang L; Yao C; Ma Y; Liu Y
Oxid Med Cell Longev; 2022; 2022():4750671. PubMed ID: 35432717
[TBL] [Abstract][Full Text] [Related]
16. Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer.
Chung CH; Lin CY; Chen CY; Hsueh CW; Chang YW; Wang CC; Chu PY; Tai SK; Yang MH
Adv Sci (Weinh); 2023 May; 10(15):e2204514. PubMed ID: 37026630
[TBL] [Abstract][Full Text] [Related]
17. Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma.
Song A; Wu L; Zhang BX; Yang QC; Liu YT; Li H; Mao L; Xiong D; Yu HJ; Sun ZJ
Cancer Lett; 2024 Apr; 588():216727. PubMed ID: 38431035
[TBL] [Abstract][Full Text] [Related]
18. miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC.
Citron F; Segatto I; Musco L; Pellarin I; Rampioni Vinciguerra GL; Franchin G; Fanetti G; Miccichè F; Giacomarra V; Lupato V; Favero A; Concina I; Srinivasan S; Avanzo M; Castiglioni I; Barzan L; Sulfaro S; Petrone G; Viale A; Draetta GF; Vecchione A; Belletti B; Baldassarre G
EMBO Mol Med; 2021 Jul; 13(7):e12872. PubMed ID: 34062049
[TBL] [Abstract][Full Text] [Related]
19. The Role of EREG/EGFR Pathway in Tumor Progression.
Cheng WL; Feng PH; Lee KY; Chen KY; Sun WL; Van Hiep N; Luo CS; Wu SM
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884633
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
